Myeloproliferative Neoplasms

Updated data from the phase 3 ASCERTAIN trial demonstrated that the oral, fixed-duration combination of decitabine and cedazuridine induced a median overall survival of 31.7 months in patients with intermediate- and high-risk myelodysplastic syndrome, including chronic myelomonocytic leukemia.

The hallmarks of myelofibrosis—including clonal myeloproliferation, bone marrow fibrosis, anemia, splenomegaly, and constitutional symptoms—are associated with risk of morbidity and mortality; however, the recent advent of novel combinations and sequencing strategies have built on the foundation of care established with JAK2 inhibitors.

The investigational JAK inhibitor momelotinib is effective at treating anemia in patients with myelofibrosis, resulting in improved rates of transfusion independence compared with ruxolitinib.

Although there are several classes of drugs either approved, or in development, for the treatment of myeloproliferative neoplasms, a big question remains.

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

The phase 2a MYLOX-1 trial is evaluating GB2064, a novel, oral LOXL2 inhibitor, as a potential anti-fibrotic treatment option for patients with myelofibrosis.

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Palbociclib plus ruxolitinib led to normalized blood leukocyte counts, reduced splenomegaly, and significantly improved bone marrow fibrosis in JAK2 V617F and MPLW515L mouse models of myelofibrosis, suggesting that the combination could provide therapeutic benefit to patients with the malignancy.

Pankit Vachhani, MD, reacts to treatment limitations for health care professionals who care for patients with myeloproliferative neoplasms.

Patient factors and disease characteristics that impact decisions to treat patients with myelofibrosis with ruxolitinib or fedratinib.

Pankit Vachhani, MD, explains how to properly treat myelofibrosis using ruxolitinib based on data provided by key clinical trials like COMFORT-I and COMFORT-II.

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

Jean-Jacques Kiladjian, MD, PhD, discusses the effectiveness of momelotinib compared with ruxolitinib in patients with myelofibrosis who have anemia and are naïve to JAK inhibitors.

Criteria and assessments that can be used to help clinicians select treatment and monitor patients on therapy for myelofibrosis.

Pankit Vachhani, MD, comments on goals of therapy for patients with myelofibrosis and highlights traditional treatment approaches.

An overview of risk stratification models available to assess and classify patients with primary myelofibrosis.

Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.

Though there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative therapeutic modality.

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

A thought leader in hematologic malignancies provides key insights into the future of treatment for polycythemia vera by considering the potential role of treatment sequencing or combination therapy.

Jamile Shammo, MD, FASCP, FACP, continues her discussion of ruxolitinib for polycythemia vera by examining the results of the RESPONSE-2 trial and sharing personal experience managing toxicity in clinic.

Renowned expert in the management of MPNs, Jamile Shammo, MD, FASCP, FACP, reviews the RESPONSE trial of ruxolitinib in patients with PV and discusses the agent’s safety and efficacy.